Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 2:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 116 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pharmacokinetics of Midazolam Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Effect of BMS-791325 on the Pharmacokinetics of Midazolam in Healthy Subjects

NCT00996879
View directory record Official record
Conditions
Hepatitis C
Interventions
Midazolam, BMS-791325
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 49 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated May 6, 2014 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Safety and Pharmacokinetics of JNJ-38518168 in Japanese and Caucasian Male Participants and the Effect of JNJ-38518168 on the Blood Levels of Midazolam

NCT01442532
View directory record Official record
Conditions
Healthy Male Volunteer
Interventions
JNJ-38518168 (30 mg), JNJ-38518168 (10 mg), JNJ-38518168 (3 mg), Placebo, Midazolam and JNJ-38518168
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 1 Interventional

Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors

NCT01596647
View directory record Official record
Conditions
Advanced Solid Tumors, Excluding Breast Cancer
Interventions
caffeine, diclofenac, omeprazole, midazolam, TKI258
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
Kansas City, Kansas • Detroit, Michigan • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of Phenytoin on the Drug Levels of Afimetoran and the Effect of Afimetoran on the Drug Levels of Midazolam

NCT05901714
View directory record Official record
Conditions
Healthy Participants
Interventions
Afimetoran, Phenytoin, Midazolam
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Sep 30, 2026, 2:32 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Drug-Interaction Assessment of GSK3772701 in Healthy Male and Female Participants Aged 18 to 55 Years

NCT07670377
View directory record Official record
Conditions
Malaria, Falciparum
Interventions
Midazolam (MDZ), GSK3772701
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of AZD5462 on the Pharmacokinetics of Midazolam, Rosuvastatin and Digoxin

NCT05395117
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD5462, Midazolam, Rosuvastatin, Digoxin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of CYP3A4 Inhibition on the Single Dose Pharmacokinetics of ASTX660 and the Effect of a Single Dose of ASTX660 on the Pharmacokinetics of the CYP3A4 Substrate Midazolam

NCT04411030
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ASTX660, Midazolam, Itraconazole
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 2, 2024 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of S-740792 in Healthy Adult Study Participants

NCT06724978
View directory record Official record
Conditions
Healthy Participants
Interventions
S-740792 Suspension, Midazolam, Placebo, S-740792 Tablet
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 55 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Pharmacokinetics of Digoxin; Sulfasalazine; and the Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan in Healthy Subjects

NCT02434861
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Rolapitant, Digoxin, Sulfasalazine, Cooperstown Cocktail
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers

NCT01766050
View directory record Official record
Conditions
Transplant Rejection
Interventions
Caffeine, Losartan, Omeprazole, Dextromethorphan, Midazolam, Belatacept
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants

NCT06973005
View directory record Official record
Conditions
Advanced Chronic Liver Disease, Healthy Participants
Interventions
AZD2389, Midazolam, Caffeine, Bupropion
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 1 Interventional

Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam

NCT02082665
View directory record Official record
Conditions
Cancer
Interventions
Rosuvastatin10 mg tablet, Midazolam 3 mg syrup, Dabrafenib 75 mg capsule
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Assessing the Pharmacokinetics and Drug Interaction Liability of Kratom, an Opioid-like Natural Product

NCT04392011
View directory record Official record
Conditions
Interaction Drug Food
Interventions
Midazolam HCl, Dextromethorphan HBr, Kratom
Drug · Dietary Supplement
Lead sponsor
Washington State University
Other
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin

NCT07118215
View directory record Official record
Conditions
Healthy Volunteers
Interventions
KarXT, Midazolam, Fexofenadine, Digoxin
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 50 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 1 Interventional

Investigate Effect of Secukinumab on the PK of Midazolam in Patients With Mod to Sev Plaque Psoriasis

NCT02607774
View directory record Official record
Conditions
Moderate to Severe Plaque Psoriasis
Interventions
Midazolam, AIN457
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
8
States / cities
Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin Drug Levels in Healthy Adults.

NCT07567781
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ABBV-722, Midazolam, Metformin, Digoxin, Pitavastatin, Sitagliptin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 30, 2026, 2:32 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

NCT06943521
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Breast Cancer, Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Prostate Cancer, Urothelial Carcinoma, Neuroendocrine Tumor (NET), Neuroendocrine Carcinoma (NEC), Soft Tissue Sarcoma, Nuclear Protein in Testis (NUT) Carcinoma
Interventions
MT-4561
Drug
Lead sponsor
Tanabe Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
Los Angeles, California • Grand Rapids, Michigan • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-986120 in Healthy Subjects and the Effects of Co-Administration of Midazolam and BMS-986120

NCT02208882
View directory record Official record
Conditions
Healthy Adult Volunteers
Interventions
BMS-986120, Placebo, Midazolam
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2015 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 1 Interventional Results available

Brodalumab Drug-Drug Interaction (DDI) and Intensive Pharmacodynamic (PK) Study in Psoriasis Subjects

NCT01937260
View directory record Official record
Conditions
Psoriasis
Interventions
Brodalumab
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
5
States / cities
Anaheim, California • Irvine, California • Ocala, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin

NCT03131973
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
BMS-986195, Methotrexate, Leucovorin, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, Pravastatin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 15, 2017 · Synced Sep 30, 2026, 2:32 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Phase 1, First-in-human Study of VX-433

NCT07584434
View directory record Official record
Conditions
Narcolepsy Type 1 (NT1)
Interventions
VX-433, Placebo, Midazolam, Bupropion
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug-drug Interaction Study With Risdiplam Multiple Dose and Midazolam in Healthy Participants

NCT03988907
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
Risdiplam, Midazolam
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Examine the Effects of Entinostat on Midazolam in Healthy Adult Subjects

NCT03187015
View directory record Official record
Conditions
Drug Interaction, Healthy Volunteer
Interventions
Entinostat, Midazolam
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
19 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Sep 30, 2026, 2:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Volunteers to Assess the Pharmacokinetics of Midazolam Administered Alone and in Combination With Vandetanib

NCT01544140
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Midazolam, vandetanib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 29, 2016 · Synced Sep 30, 2026, 2:32 AM EDT